360 related articles for article (PubMed ID: 25286304)
1. Gene therapy for eye as regenerative medicine? Lessons from RPE65 gene therapy for Leber's Congenital Amaurosis.
Rakoczy EP; Narfström K
Int J Biochem Cell Biol; 2014 Nov; 56():153-7. PubMed ID: 25286304
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Ocular Gene Therapy in an Italian Patient Affected by Congenital Leber Amaurosis Type 2 Treated in Both Eyes.
Testa F; Maguire AM; Rossi S; Marshall K; Auricchio A; Melillo P; Bennett J; Simonelli F
Adv Exp Med Biol; 2016; 854():533-9. PubMed ID: 26427456
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of gene therapy on Leber's congenital amaurosis.
Bainbridge JW; Mehat MS; Sundaram V; Robbie SJ; Barker SE; Ripamonti C; Georgiadis A; Mowat FM; Beattie SG; Gardner PJ; Feathers KL; Luong VA; Yzer S; Balaggan K; Viswanathan A; de Ravel TJ; Casteels I; Holder GE; Tyler N; Fitzke FW; Weleber RG; Nardini M; Moore AT; Thompson DA; Petersen-Jones SM; Michaelides M; van den Born LI; Stockman A; Smith AJ; Rubin G; Ali RR
N Engl J Med; 2015 May; 372(20):1887-97. PubMed ID: 25938638
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.
Simonelli F; Maguire AM; Testa F; Pierce EA; Mingozzi F; Bennicelli JL; Rossi S; Marshall K; Banfi S; Surace EM; Sun J; Redmond TM; Zhu X; Shindler KS; Ying GS; Ziviello C; Acerra C; Wright JF; McDonnell JW; High KA; Bennett J; Auricchio A
Mol Ther; 2010 Mar; 18(3):643-50. PubMed ID: 19953081
[TBL] [Abstract][Full Text] [Related]
5. The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.
Pierce EA; Bennett J
Cold Spring Harb Perspect Med; 2015 Jan; 5(9):a017285. PubMed ID: 25635059
[TBL] [Abstract][Full Text] [Related]
6. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
Stein L; Roy K; Lei L; Kaushal S
Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
[TBL] [Abstract][Full Text] [Related]
7. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
[TBL] [Abstract][Full Text] [Related]
8. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
[TBL] [Abstract][Full Text] [Related]
9. Seeing is believing: gene therapy shows promise for ocular disorders.
Friedrich MJ
JAMA; 2010 Oct; 304(14):1543-5. PubMed ID: 20940376
[No Abstract] [Full Text] [Related]
10. Gene therapy for RPE65-related retinal disease.
Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for Leber congenital amaurosis: advances and future directions.
Hufnagel RB; Ahmed ZM; Corrêa ZM; Sisk RA
Graefes Arch Clin Exp Ophthalmol; 2012 Aug; 250(8):1117-28. PubMed ID: 22644094
[TBL] [Abstract][Full Text] [Related]
12. Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis.
Hussain RM; Tran KD; Maguire AM; Berrocal AM
Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):661-663. PubMed ID: 31671202
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
[TBL] [Abstract][Full Text] [Related]
14. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
[TBL] [Abstract][Full Text] [Related]
15. Available Evidence on Leber Congenital Amaurosis and Gene Therapy.
Alkharashi M; Fulton AB
Semin Ophthalmol; 2017; 32(1):14-21. PubMed ID: 27686653
[TBL] [Abstract][Full Text] [Related]
16. Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.
Georgiadis A; Duran Y; Ribeiro J; Abelleira-Hervas L; Robbie SJ; Sünkel-Laing B; Fourali S; Gonzalez-Cordero A; Cristante E; Michaelides M; Bainbridge JW; Smith AJ; Ali RR
Gene Ther; 2016 Dec; 23(12):857-862. PubMed ID: 27653967
[TBL] [Abstract][Full Text] [Related]
17. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel.
Banin E; Bandah-Rozenfeld D; Obolensky A; Cideciyan AV; Aleman TS; Marks-Ohana D; Sela M; Boye S; Sumaroka A; Roman AJ; Schwartz SB; Hauswirth WW; Jacobson SG; Hemo I; Sharon D
Hum Gene Ther; 2010 Dec; 21(12):1749-57. PubMed ID: 20604683
[TBL] [Abstract][Full Text] [Related]
18. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.
Cideciyan AV; Jacobson SG; Beltran WA; Sumaroka A; Swider M; Iwabe S; Roman AJ; Olivares MB; Schwartz SB; Komáromy AM; Hauswirth WW; Aguirre GD
Proc Natl Acad Sci U S A; 2013 Feb; 110(6):E517-25. PubMed ID: 23341635
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
Maguire AM; High KA; Auricchio A; Wright JF; Pierce EA; Testa F; Mingozzi F; Bennicelli JL; Ying GS; Rossi S; Fulton A; Marshall KA; Banfi S; Chung DC; Morgan JI; Hauck B; Zelenaia O; Zhu X; Raffini L; Coppieters F; De Baere E; Shindler KS; Volpe NJ; Surace EM; Acerra C; Lyubarsky A; Redmond TM; Stone E; Sun J; McDonnell JW; Leroy BP; Simonelli F; Bennett J
Lancet; 2009 Nov; 374(9701):1597-605. PubMed ID: 19854499
[TBL] [Abstract][Full Text] [Related]
20. [Gene therapy for vision restoration in patients with Leber congenital amaurosis (LCA) due to RPE65 gene mutations: beginning the phase IV trial].
Chacón-Camacho ÓF; Zenteno JC
Gac Med Mex; 2017; 153(2):276-278. PubMed ID: 28474714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
